Sudeep Pharma IPO

Sudeep Pharma IPO: Check IPO Date, Live Subscription and Key Details

Sudeep Pharma is a technology-led manufacturer of **excipients** and **specialty mineral ingredients** used globally in pharmaceutical, food, and nutrition industries. The company utilizes in-house technologies such as encapsulation, spray drying, and liposomal preparations to produce high-value mineral-based ingredients (calcium, iron, zinc, etc.). Sudeep Pharma is one of the largest producers of food-grade iron phosphate globally and is one of the few companies with a USFDA-approved facility for manufacturing mineral-based ingredients. It serves over 1,100 customers worldwide, including major names like **Pfizer, Merck, Danone, Intas, and Mankind**.

Price Range
₹563.0 - ₹593.0
Issue Size
₹895 Crore
Lot Size
25 shares
IPO Type
Mainboard
GMP
₹118(+19.90%)
Est. Listing Price
₹711

Key Metrics

Check Live GMP

Face Value
₹1
EPS
11.07
P/E Ratio
53.55
RoNW
27.88%
ROE
27.88%
Debt to Equity
0.2
Advertisement

Timeline

IPO Opens

21 Nov

IPO Closes

25 Nov

Allotment

26 Nov

Listing

28 Nov

IPO Timeline & Listing Details

EventDate
IPO Open Date21 November 2025
IPO Close Date25 November 2025
Allotment Date26 November 2025
Listing Date28 November 2025

Investment Categories

CategoryLotsAmount
Retail (Min)
1₹14,825
Retail (Max)Just less than ₹2,00,000
13₹1,92,725
SHNI (Min)Just above ₹2,00,000
14₹2,07,550
SHNI (Max)Below ₹10,00,000
67₹9,93,275
BHNIAbove ₹10,00,000
68₹10,08,100

IPO Objectives

  • Capital expenditure towards procurement of machinery for the production line located at Nandesari Facility I (₹75.81 Cr).
  • General corporate purposes.

Strengths

  • The company has a market leadership position with a diversified portfolio in the high-barrier, regulated niche of pharma excipients and specialty ingredients.
  • It boasts a distinguished global customer base of over 1,100 customers, including major pharmaceutical companies like Pfizer and Merck.
  • The manufacturing facilities are globally compliant (USFDA, BRC, WHO-GMP, etc.), which creates a strong barrier to entry.
  • The business has strong research and development capabilities focused on advanced technologies like encapsulation and liposomal preparations.
  • It shows high profitability with an EBITDA Margin of 39.7% and RoNW of 27.88% in FY25, placing it among high-performing specialty chemical players.

Weaknesses

  • The post-IPO P/E of 53.55x is considered aggressively priced, leaving limited room for short-term listing gains.
  • The ₹800 Cr Offer for Sale (OFS) means the majority of the proceeds will go to the selling shareholders, not for the company's growth.
  • The company is facing working capital strains due to a significant increase in net working capital days, indicating weak cash conversion.
  • Revenue Concentration: The top 10 customers contribute over 35% of revenues, increasing vulnerability to client-level slowdowns.
  • The business has exposure to FX sensitivity and geopolitical developments, as exports account for a significant portion of sales (59-68%).
Advertisement

Financial Performance

Period Ended30 Jun 202531 Mar 202531 Mar 202431 Mar 2023
Assets (₹ Cr.)922.26717.17513.87420.11
Revenue (₹ Cr.)130.08511.33465.38438.26
PAT (₹ Cr.)31.27138.69133.1562.32
Net Worth (₹ Cr.)688.32497.53359.07226.29

Peer Comparison

CompanyP/B RatioP/E RatioRONW (%)Net Worth (₹ Cr.)
Sudeep Pharma Ltd.12.9353.5527.88%688.32
Anupam Rasayan4.1960.164.73%3,082

Subscription Details

Daily Bids Status

CategoryDay 1
QIB0.09x
NII3.01x
S-HNI3.53x
B-HNI2.75x
RII1.53x
Total1.43x

Overall Subscription Statistics

CategoryShares OfferedShares BidBid Amount (₹ Cr)
QIB30,18,5532,69,92516.01
NII22,63,91268,11,775403.94
Small NII7,54,63726,66,000158.09
Big NII15,09,27541,45,775245.84
RII52,82,46280,63,700478.18
Total1,05,64,9271,51,45,400898.12
Advertisement

Company Details

  • Sudeep Pharma Ltd.
  • 129/1/A, GIDC Estate, Nandesari, Vadodara, Gujarat - 391340
  • +91 265 284 0656
  • cs.sudeep@sudeepgroup.com
  • https://www.sudeeppharma.com/

Registrar Details